Alltrna, a startup developing a new class of RNA-based drugs where a single therapy could potentially be reused across many different diseases, has received clearance to begin its first clinical trial, the company told Endpoints …
Pharma’s dealmaking tear; Blackstone raises record fund; Xolair energizes allergy research; and more
Welcome back to Endpoints Weekly! They say March comes in like a lion and out like a lamb, but two pharma giants made a roar


